Skip to main content
. 2015 Jun 11;16(6):13427–13441. doi: 10.3390/ijms160613427

Figure 5.

Figure 5

Distribution of myelin proteins and other biomarker candidates in intact and infarcted brain tissue. (A) Three myelin proteins from zones 4–6 of intact brain tissues were verified and semi-quantified by LCM–LRP. Each protein was verified by 2–4 unique peptides and quantified by the peak area. Peak area ratios of unique peptides to RP* were calculated (UP/RP*) (n = 12); (B) Three unique myelin proteins in zones 1–3 of infarcted brain tissue were collected by LCM, and then the peak area ratios of 3 unique peptides to RP* were calculated (UP/RP*) (n = 12); (C) Two protein biomarker candidates from zones 4–6 were verified by 2–3 unique peptides for each and quantified by the peak area. Peak area ratios of unique peptides to RP* were calculated (UP/RP*) (n = 12); (D) The peak area ratios of NSE-P1 and UCHL1-P1 (UP/RP*) in zones 1–3 were calculated (n = 12). Unique peptide 1 for myelin basic protein (MBP-P1), DTGILDSIGR; unique peptide 1 for myelin proteolipid protein (PLP-P1), TSASIGSLCADAR; unique peptide 1 for 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP-P1), AIFTGYYGK; unique peptide 1 for neuron-specific enolase (NSE-P1), LGAEVYHTLK; unique peptide 1 for ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1-P1), FSAVALCK. * p < 0.05; ** p < 0.01.